Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses

Journal of Infectious Diseases

Volumn 209, Issue 7, 2014, Pages 995-1006

  Agnihothram, Sudhakar ^a,b   Gopal, Robin ^d   Yount, Boyd L ^a,b   Donaldson, Eric F ^a,b   Menachery, Vineet D ^a,b   Graham, Rachel L ^a,b   Scobey, Trevor D ^a,b   Gralinski, Lisa E ^a,b   Denison, Mark R ^c   Zambon, Maria ^d   Baric, Ralph S ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Diagnostics; MERS CoV Vaccine Design; Serology; Synthetic Genomics

Indexed keywords

NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; VIRUS SPIKE PROTEIN;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORONAVIRUS; CROSS REACTION; HUMAN CORONAVIRUS NL63; HUMAN CORONAVIRUS OC43; MIDDLE EASTERN RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SARS CORONAVIRUS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

DIAGNOSTICS; MERS-COV VACCINE DESIGN; SEROLOGY; SYNTHETIC GENOMICS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; CHIROPTERA; CORONAVIRIDAE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEUTRALIZATION TESTS; NUCLEOCAPSID PROTEINS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 84898978774     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit609     Document Type: Article

References (42)

1. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: Mechanisms of coronavirus cross-species transmission. J Virol 2010; 84:3134-46
2. Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006; 66:193-292. (Pubitemid 44107834
3. Pyrc K, Sims AC, Dijkman R, et al. Culturing the unculturable: Human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J Virol 2010; 84: 11255-63
4. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10:368-73. (Pubitemid 38508514
5. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-9. (Pubitemid 36638152
6. Lau SK, Li KS, Tsang AK, et al. Genetic characterization of Betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: Implications on the origin of the novel Middle East respiratory syndrome coronavirus. J Virol 2013; 87:8638-50
7. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012; 17:20290
8. Huynh J, Li S, Yount B, et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol 2012; 86:12816-25
9. van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3:e00473-12
10. Müller MA, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3:e00515-12
11. Bolles M, Donaldson E, Baric R. SARS-CoVand emergent coronaviruses: Viral determinants of interspecies transmission. Curr Opin Virol 2011; 1:624-34
12. Perlman S, Zhao J. Human coronavirus EMC is not the same as severe acute respiratory syndrome coronavirus. MBio 2013; 4:e00002-13
13. Deming D, Sheahan T, Heise M, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006; 3:e525
14. Rockx B, Corti D, Donaldson E, et al. Structural basis for potent crossneutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol 2008; 82:3220-35. (Pubitemid 351429902
15. Chan RW, Chan MC, Agnihothram S, et al. Tropism and innate immune responses of the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013; 87:6604-14
16. Josset L,MenacheryVD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 2013; 4:e00165-13
17. Sheahan T, Whitemore A, Long K, et al. Successful vaccination strategies that protect agedmice fromlethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 2011; 85:217-30
18. Donaldson EF, Sims AC, Graham RL, Denison MR, Baric RS. Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. J Virol 2007; 81:6356-68. (Pubitemid 46878042
19. Höschler K, Gopal R, Andrews N, et al. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/ 1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza Other Respi Viruses 2007; 1:199-206
20. Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2013; 110:16157-62
21. Sheahan T, Whitmore A, Long K, et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 2011; 85:217-30
22. Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87:5502-11
23. Becker MM, Graham RL, Donaldson EF, et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A 2008; 105:19944-9
24. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67:130-40
25. Giménez LG, Rojas J, Rojas A, Mendoza J, Camacho AG. Development of an enzyme-linked immunosorbent assay-based test with a cocktail of nucleocapsid and spike proteins for detection of severe acute respiratory syndrome-Associated coronavirus-specific antibody. Clin Vaccine Immunol 2009; 16:241-5
26. Vega VB, Ruan Y, Liu J, et al. Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003. BMC Infect Dis 2004; 4:32
27. Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013; 31:943-9
28. Wecker M, Gilbert P, Russell N, et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 2012; 19:1651-60
29. Fillis CA, Calisher CH. Neutralizing antibody responses of humans and mice to vaccination with Venezuelan encephalitis (TC-83) virus. J Clin Microbiol 1979; 10:544-9
30. Tesh RB, Gajdusek DC, Garruto RM, Cross JH, Rosen L. The distribution and prevalence of group A arbovirus neutralizing antibodies among human populations in Southeast Asia and the Pacific islands. Am J Trop Med Hyg 1975; 24:664-75
31. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7:e35421
32. Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011; 85:12201-15
33. Ben-Yehuda A, Ehleiter D, Hu AR,Weksler ME. Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. J Infect Dis 1993; 168:352-7. (Pubitemid 23210611
34. Asanuma H, Hirokawa K, Uchiyama M, et al. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine. Vaccine 2001; 19:3981-9. (Pubitemid 32566323
35. Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest 2011; 121:4921-30
36. Munster VJ, deWit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med 2013; 368:1560-2
37. Fine DL, Roberts BA, Teehee ML, et al. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 2007; 25:1868-76
38. Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 2008; 26:3497-506
39. Dea S, Verbeek AJ, Tijssen P. Antigenic and genomic relationships among turkey and bovine enteric coronaviruses. J Virol 1990; 64:3112-8. (Pubitemid 20171313
40. Hogue BG, King B, Brian DA. Antigenic relationships among proteins of bovine coronavirus, human respiratory coronavirus OC43, and mouse hepatitis coronavirus A59. J Virol 1984; 51:384-8. (Pubitemid 14091426
41. Cao Z, Liu L, Du L, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 2010; 7:299
42. Memish ZA, Zumla AI, Assiri A. Middle east respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013; 369:884-6